Debate continues over school head lice policies as parents call for stricter exclusion rules while public health guidance supports in-class management.
The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.